SS
Therapeutic Areas
Incyte Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Jakafi (ruxolitinib) | Myelofibrosis | Marketed |
| Opzelura (ruxolitinib cream) | Atopic Dermatitis | Marketed |
| Pemazyre (pemigatinib) | Cholangiocarcinoma | Marketed |
| Zynyz (retifanlimab) | Merkel Cell Carcinoma | Marketed |
| Iclusig (ponatinib) | CML, Ph+ ALL | Marketed |
| Tabrecta (capmatinib) | NSCLC (METex14) | Marketed |
| Ruxolitinib + INCB106385 | Myelofibrosis (LIMBER) | Phase 3 |
| Ruxolitinib + INCB057643 | Myelofibrosis (LIMBER) | Phase 2 |